Program
PF-07976016
A development code. Also written as “PF-07976016 Formulation A” and “PF-07976016 Formulation B”.
Its studies are mostly in Obesity, led by Pfizer.
Furthest: phase 2, since Dec 2, 20244 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 40 open or running | phase 2since Dec 2, 2024 | Oct 31, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 31, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06670170 · 12 enrolled · United States
- Dec 2, 2024Phase 2 study in ObesityNCT06717425 · 263 enrolled · United States, Canada, Poland
- Mar 12, 2025Phase 1 study in OverweightNCT06910839 · 21 enrolled · United States
- Jun 3, 2025Phase 1 study in Healthy Male VolunteersNCT07015918 · 8 enrolled · Netherlands
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07015918Healthy Male Volunteers · Netherlands | 1 | Completed | Jul 16, 2025 | 8 |
| NCT06910839Overweight · United States | 1 | Terminated | May 1, 2025 | 21 |
| NCT06717425Obesity · United States, Canada, Poland | 2 | Completed | Oct 23, 2025 | 263 |
| NCT06670170Healthy Volunteers · United States | 1 | Completed | Dec 24, 2024 | 12 |
How it is read
Names in the registry
- “PF-07976016”, 3 entries
- “PF-07976016 Formulation A”, 1 entry
- “PF-07976016 Formulation B”, 1 entry
Codes read as this program: PF07976016.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.